A detailed history of Arlington Financial Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Arlington Financial Advisors, LLC holds 500 shares of VRTX stock, worth $230,855. This represents 0.06% of its overall portfolio holdings.

Number of Shares
500
Previous 535 6.54%
Holding current value
$230,855
Previous $250,000 7.2%
% of portfolio
0.06%
Previous 0.07%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$460.0 - $505.78 $16,100 - $17,702
-35 Reduced 6.54%
500 $232,000
Q2 2024

Jul 16, 2024

BUY
$392.81 - $485.53 $13,748 - $16,993
35 Added 7.0%
535 $250,000
Q4 2023

Jan 08, 2024

BUY
$343.0 - $410.68 $171,500 - $205,340
500 New
500 $203,000
Q4 2020

Jan 29, 2021

SELL
$207.01 - $276.09 $186,309 - $248,480
-900 Closed
0 $0
Q1 2020

Apr 09, 2020

BUY
$199.77 - $247.81 $179,793 - $223,029
900 New
900 $214,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Arlington Financial Advisors, LLC Portfolio

Follow Arlington Financial Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arlington Financial Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Arlington Financial Advisors, LLC with notifications on news.